Abstract-Success with oncologic treatment has allowed cancer patients to experience longer cancer-free survival gains.
M
ortality from cancer has decreased tremendously over the past few decades, in part, through earlier diagnosis and novel treatments. Unfortunately, although cancer-free survival has increased, complications from cancer therapy, particularly effects of cardiac function have limited patient outcomes, impacting the overall morbidity and mortality adversely. 1 Heart failure (HF) as a result of cancer therapy has been linked to a 3.5-fold increased mortality risk compared with idiopathic cardiomyopathy. 2 An integrative approach between the oncologist and cardiologist can aid in minimizing these detrimental effects. In the second part of this 2-part review, we discuss evaluation, surveillance, prevention, and treatment in this patient population. We highlight a proposed algorithm for approaching these patients before, during, and following cancer therapy. We conclude highlight challenges within the field and areas that need further research.
Prevention Strategies β-Blockers
There is growing evidence suggesting a cardioprotective role of β-blockers in prevention of anthracycline-induced cardiotoxicity. Carvedilol, which is also an antioxidant and has the ability to chelate iron, prevented cardiac histopathology caused by doxorubicin. 3 Carvedilol may prevent strain abnormalities after anthracycline use. 4 In studies with carvedilol 5 and nebivolol 6 at initiation of anthracycline use, both agents resulted in higher degree of left ventricular ejection fraction (LVEF) preservation. The use of β-blockers during treatment with trastuzumab and anthracyclines was associated with a lower incidence of HF over a 5-year period. 7 Although carvedilol and nebivolol are beneficial, nonselective β-blockers, such as propranolol, may in fact be cardiotoxic, 8 and the effect of metoprolol is neutral. 
Renin-Angiotensin Inhibitors
Animal studies suggest that angiotensin-converting enzyme inhibitors (ACEI) may be cardioprotective in anthracycline toxicity. 10 Enalapril treatment 1 week before doxorubicin and continued for 3 weeks after the last dose preserved mitochondrial function and downregulated free-radical generation. 11 Beneficial mechanisms include attenuation of fibrosis and oxidative stress and decreased angiotensin-induced blockade of the neuregulin/ERb system. 12 Some data on ACEI benefit in reducing chemotherapy-related HF have been disappointing, 9, 13 although criticism of these trials included delay in initiation and broad enrollment of patients on multiple chemotherapy regimens. The benefit of a prophylactic ACEI strategy may be enhanced with risk stratification. Treatment with enalapril using troponin I elevation to identify and stratify high-risk anthracycline patients prevented reduction in LVEF and the development of cardiotoxicity. 14 The role of ACEI in trastuzumab or radiation-treated patients has not yet been extensively studied. Telmisartan, when administered immediately before epirubicin, may reduce the formation of reactive oxygen species and attenuate the development of myocardial dysfunction in patients receiving higher doses of epirubicin.
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Aldosterone Antagonist Therapy and Other HF Therapies
Aldosterone antagonists have been speculated to attenuate trastuzumab-induced myocardial dysfunction through inhibition of the EGFR receptor, though further study is warranted. 16 Spironolactone, used simultaneously with anthracyclines in breast cancer patients with preserved left ventricular (LV) function, may attenuate left ventricular dysfunction (LVD) suggesting a role in prevention of both systolic and diastolic dysfunctions. 17 The role of other agents used in HF management, such as hydralazine/nitrates and digoxin, has not been studied in the cancer cardiotoxicity population; however, guideline derived medical treatment in general should be employed in all patients with LVD.
Combination Therapy
The OVERCOME trial (Prevention of Left Ventricular Dysfunction with Enalapril and Carvedilol in Patients Submitted to Intensive Chemotherapy for the Treatment of Malignant Hemopathies) used a combination of carvedilol and enalapril in patients with leukemia or those planned for stem cell transplantation. In patients who received combination therapy, there was no reduction in LVEF compared with those who received placebo. In addition, patients on combination therapy had a lower incidence of death or HF. 18 Preliminary results of the Prevention of Cardiac Dysfunction during Adjuvant Breast Cancer Therapy (PRADA) trial revealed that candesartan, but not metoprolol tartrate, prevented a modest short-term decline in LVEF during anthracycline inclusive breast cancer therapy as measured by cardiac magnetic resonance imaging. Longer term follow-up will further establish a preventative role of angiotensin receptor blockade. 19, 20 MANTICORE-101 (Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research) is examining the use of perindopril versus bisoprolol in patients with human epidermal growth factor receptor (HER2+) breast cancer undergoing treatment with trastuzumab in the prevention of LVD as assessed by cardiac magnetic resonance imaging.
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Dexrazoxane
Dexrazoxane, a derivative of the metal-chelating agent EDTA, is thought to attenuate anthracycline cardiac toxicity through iron chelation and decrease in production of free radicals. 22 In addition, dexrazoxane binds to topoisomerase 2, preventing the formation of anthracycline-mediated DNA-Top2 complexes. 23 In patients treated with anthracyclines, dexrazoxane decreased HF risk and increased cardiac event-free survival. 24 However, the mechanism by which dexrazoxane provides cardioprotection has raised concerns that this agent may attenuate doxorubicin antitumor activity, through binding to both Top2-α and Top2-β. 25 Clinical trial data are inconclusive, but a Cochrane review demonstrated no difference in efficacy of anthracyclines against the primary malignancy with the addition of dexrazoxane. 23 The American Society of Clinical Oncology recommends that use of dexrazoxane should be limited to adult patients in the metastatic breast cancer setting and other malignancies who have received >300 mg/m 2 and who may benefit from use of additional anthracyclines. 26 Recent data demonstrated long-term efficacy in reducing HF in cancer survivors from the pediatric cohort, 27 and therefore, new studies are required to determine safety and efficacy in adult cancer populations. A meta-analysis on the prophylactic use of dexrazoxane in patients receiving anthracyclines revealed a decrease in cardiac events.
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Statins 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, in addition to their lipid lowering, exert cardioprotective effects through pleiotropic mechanisms. Studies suggest the benefit of statins in reducing anthracycline-mediated cardiomyocyte death. 29 In a retrospective cohort study of >600 cancer patients, uninterrupted statin use resulted in reduced HF. 30 In patients without preexisting cardiovascular abnormalities, prophylactic atorvastatin led to higher preservation of LVEF. 31 To date, no prospective trials have addressed the role of statins in the prevention of cancer therapy-related cardiotoxicity (Table 1) .
Primordial Versus Primary Versus Secondary Prevention
Prevention may be primary, extended to all patients already treated with potentially cardiotoxic therapies, or secondary in selected high-risk patients showing preclinical signs of cardiotoxicity as in the form of biomarker increase, strain decrease, etc. More recently, the concept of primordial prevention with cardioprotective therapies has been described to address the population of patients immediately after initial cancer diagnosis but preceding cancer therapy. 33 A tailored prevention strategy based on the cardiac risk stratification according to patient-related (including genetic predisposition) and to therapy-related risk factors bears further investigation.
Treatment of LVD and HF
Conventional therapy with β-blockers and ACEI in LVD and HF is extrapolated to patients with chemotherapy-induced cardiotoxicity, although randomized trial data are lacking. Enalapril and carvedilol given 1 to 2 months after anthracycline therapy in patients with LVD led to LVEF recovery in most cases; however, when treatment was delayed, recovery was partial or absent. 34 In another study, patients with LVD, regardless of the presence of symptoms, were given either enalapril (before 1999) or enalapril and β-blocker (carvedilol or bisoprolol after 1999) and showed recovery of LVEF with greater improvement with combined therapy. 35 The role of HF treatment in trastuzumab-induced LVD has not been established ( Table 2) . 36, 37 The presence of high-risk features should prompt cardio-oncology consultation. Incorporation of biomarkers is recommended, although their role in routine monitoring is not fully established. 37, 38 The frequency and intervals with which to image patients vary with risk factors, type of chemotherapy, and planned dosing, 38 and are currently center-dependent. Radiation therapy requires a different surveillance algorithm 38, 39 because of the potential for delayed cardiac dysfunction (Figure) .
Not all asymptomatic left ventricular dysfunction and HF that develop during or after cancer therapy can be assumed to be the direct result of treatment, and thus, all new or worsening cardiac dysfunction should be evaluated according to guideline recommendations. This should include evaluation for other reversible causes of myocardial dysfunction and ischemic evaluation in those patients in whom suspicion is high. 40 Higher suspicion for alternate causes is especially important in both older individuals and those with multiple comorbidities. 38 
Alterations in Cancer Therapy in Patients With Ventricular Dysfunction and HF
The Food and Drug Administration recommends withholding trastuzumab for at least 4 weeks if LVEF drops ≥16% from pretreatment values or if it falls below normal and ≥10% absolute decrease in LVEF from pretreatment values. The agent can be resumed if the LVEF returns to normal and the absolute decrease from baseline is ≤15% within 4-8 weeks. 41 It is also recommended to discontinue doxorubicin in patients who develop HF. 42 The indications for withdrawal or withholding of therapy in patients with asymptomatic LVEF decline are not as clear. ARB indicates angiotensin receptor blocker; CHOP, cylophosphamide, hydroxydaunorubicin, oncovin, prednisone; CI, confidence interval; E, early diastolic mitral inflow velocity; E/A, early diastolic mitral inflow velocity/late diastolic mitral inflow velocity; EF, ejection fraction; HF, heart failure; HL, Hodgkin's lymphoma; LVEF, left ventricular ejection fraction; LVEDD, left ventricular end-diastolic diameter; LVESD, left ventricular end-systolic diameter; LVSD, left ventricular systolic dysfunction; NHL, non-Hodgkin's lymphoma; NT-proBNP, n-terminal pro-brain natriuretic peptide; RAAS, renin-angiotensin-aldosterone system; RCT, randomized controlled trial; RF, risk factor; Rx, treatment; and TD, tissue doppler. recommendations for stopping/restarting directly reflect those used in the largest adjuvant trastuzumab trials, based on baseline systolic function and degree of LVEF % decline. 43 Decisions on alteration in dosing or discontinuation of cancer treatment need to be weighed against oncologic risk and require collaboration between cardiologists and oncologists, personalizing the strategy to the individual patient and their prognosis. Predictors of LV recovery are poorly understood. Retrospective data have suggested that LV recovery can be expected in roughly 50% of patients who develop cancer therapy-related cardiotoxicity, and that younger age, smaller left atrial volume, and lower brain natriuretic peptide (BNP) levels may be multivariate predictors of LV recovery.
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Advanced HF Therapies in the Cancer Population
Similar to the non-cancer HF population, option for therapies in the chemotherapy-induced cardiomyopathy population includes implantable cardioverter defibrillator and chronic resynchronization therapy, LV assist devices, and orthotopic heart transplantation. In a recent study, patients with adriamycin-induced cardiomyopathy derived a similar echocardiographic and clinical benefit with chronic resynchronization therapy compared with other nonischemic patients. 45 About 2.5% of nonischemic cardiomyopathy patients undergoing transplantation have chemotherapy-related cardiotoxicity, and survival is comparable with that of other nonischemic etiologies. 46 Not surprisingly, cancer patients with cardiac toxicity are more likely to undergo mechanical circulatory support as destination therapy rather than as bridge to transplant, given the obligatory 5-year cancer-free survival as a requisite for transplant candidacy. Overall survival after mechanical circulatory support in these patients is 73% at 1 year and 63% at 5 years, also similar to the general population. 47 Importantly, chemotherapy-related cardiomyopathy patients have higher rates of right ventricular dysfunction and, thus, are more likely to require right ventricular mechanical support. Nevertheless, cancer patients requiring mechanical circulatory support and orthotopic heart transplantation should be evaluated and considered appropriately for these advanced therapies.
Current Guidelines
Several groups have published recommendations and consensus statements in the adult cancer population, [36] [37] [38] 48 but formal guidelines for prevention, surveillance, and treatment of cancer therapy-related cardiac toxicity are not yet available. Currently, the American College of Cardiology/American Heart Association HF guidelines report that agents, such as anthracyclines, trastuzumab, cyclophosphamide, taxanes, 5-fluorouracil, and interferons, may cause cardiotoxicity, and dexrazoxane is cardioprotective against anthracycline-induced cardiotoxicity. 49 However, there are no specific monitoring recommendations. The European Society of Cardiology HF guidelines are similar and also recommend pre-and posttherapy LVEF evaluation and discontinuation of chemotherapy along with initiation of standard HF therapy once LVD ensues. 50 The Canadian Trastuzumab Working group recommends baseline and 3-month interval imaging assessment for all patients under trastuzumab treatment, advocating for more frequent/stringent assessments in those patients at higher risk. 51 The American Society of Echocardiography suggests echocardiography for baseline and follow-up monitoring, but there are no specific recommendations regarding frequency or duration of follow-up. 52 American Society of Clinical Oncology 26 American Society of Clinical Oncology reports that there is currently no standard strategy for long-term monitoring through biomarkers or imaging and no direct evidence regarding the treatment of LVD in asymptomatic patients 1 (Table 3) .
Knowledge Gaps and Future Directions
The specialty of cardio-oncology has gained significant momentum, with increasing awareness and interest in advancing the field. This parallels the larger armamentarium of therapies now available to patients with cancer, many of which have redefined life expectancy. There are, however, multiple gaps in the field, which bear addressing (Table 4 ). At present, there are no internationally published guidelines to address this specific patient population, and no standardized classification system to define cancer-related cardiac toxicity, LVD, and HF. Cardio-oncology guidelines will need to account for different subpopulations, such as those with metastatic and nonmetastatic disease. Furthermore, defining cardiac dysfunction through LVEF alone is insufficient. LVEF estimation may predict development of later cardiotoxicity but may not be sensitive enough to assess early preclinical changes, which might impact on management decisions. Currently, incidence of cancer therapy-related LVD and HF are likely underestimated, representing the typically younger and healthier population in largest cancer trials. Standardization of cardiac toxicity definitions will allow for prospective study of epidemiology. There are various limitations in our understanding of optimal clinical management of cardiac disease in the cancer population. At present, the largest focus has centered on HF reduced ejection fraction, but the incidence and management of HF preserved ejection fraction is largely unknown. Clinical trials addressing prevention, prophylactic medical therapy, length and types of therapy once cardiotoxicity develops, and the safety of rechallenging with cancer therapy, all remain critical unaddressed issues. Furthermore, prospectively validated risk predictive models would help clinicians to individualize care, tailor biomarker and imaging surveillance strategies, and initiate early or prophylactic medical therapy for those patients in highest risk categories. Another issue is cardioprotection during reinitiation of the culprit chemotherapy in the context of optimizing cancer Consider earlier imaging if higher baseline risk. ACE-I, indicates angiotensin-converting enzyme inhibitors; BB, beta-blocker; CAD, coronary artery disease; CHF, congestive heart failure; CMR, cardiac magnetic resonance; D/C, discontinue; HTN, hypertension; Hx, history; LVD, left ventricular dysfunction; MI, myocardial infarction; MUGA, multigated acquisition scan; RT, radiation therapy; and Sx, symptoms.
outcomes for patients with previous cancer therapy-related cardiotoxicity.
There is a lack of universal agreement on prospective cardiovascular screening, especially for newer chemotherapeutic agents and for treatment strategies that require dual or additive therapy. Further understanding of drug mechanisms would allow for more targeted prevention and treatment. Echocardiographic imaging remains critical to surveillance. The addition of strain/speckle tracking shows promise, but the additive role of this technique in routine practice requires further definition.
There is limited understanding on the long-term effect of modest LVEF declines during therapy, the implications of dose interruptions and treatment delays in cancer therapy, and how cardiac interventions impact on long-term cardiac and cancer survival. Altering cancer treatment without strong supportive data may put patients at risk of undertreatment or decreased efficacy of therapy. Although all patients receiving anthracyclines should be considered to have some degree of cardiac toxicity, choosing which patients command dose alterations or treatment discontinuation remains arbitrary, with potentially far reaching implications on survival. The term actionable cardiotoxicity has been put forth to address the when and if of treatment alterations. 53 Cardiac progenitor cells may play a role in the treatment and prevention of anthracycline-induced cardiotoxicity and may be considered as a potential translational therapy in the future, helping to promote cardiac repair. Autologous cardiac progenitor cells can be obtained before antineoplastic drugs are given to cancer patients and subsequently administered to individuals who are particularly predisposed to cardiotoxicity. 54 Significant individual variability in tolerance to cumulative anthracycline dose has suggested a role for genetic susceptibility. The clinical significance of this remains unknown but with further study may allow for more personalized oncologic therapy.
Conclusion
With survival gains in cancer therapy, attention and recognition of cardiac toxicities in cancer patients has become increasingly critical. Patients with cancer, either with preexisting cardiac disease or increased cardiac risk, require individualized risk stratification strategies. Patients who develop myocardial dysfunction during therapy often require modifications or withdrawal of life-saving cancer therapies, with profound implications on clinical outcome. Preclinical identification of cardiac toxicities may allow oncologists to continue cancer therapy without interruption. An evidence-based approach would allow enhanced delivery of care to this patient population. This can only be accomplished by further investigation and through a partnership between cardiologist and oncologist, increasingly delivered via formal cardio-oncology services with access to a multidisciplinary team effort to ensure optimal patient outcomes.
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